Table 2.
Characteristics of Qualifying Migraine at the Time of Treatment and Symptom Relief/Freedom at 2 Hours Post‐Dose (mITT Population)
| Placebo, n = 77, n (%) | ADAM Zolmitriptan 3.8 mg, n = 82, n (%) | P value † | |
|---|---|---|---|
| Characteristics of qualifying migraine | |||
| Photophobia present | 75 (97) | 78 (95) | — |
| Phonophobia present | 72 (94) | 71 (87) | — |
| Nausea present | 51 (66) | 59 (72) | — |
| Outcomes 2 hours post‐dose | |||
| Pain relief ‡ | 40 (59) | 55 (80) | <.01 |
| Photophobia‐free | 32 (42) | 57 (70) | <.01 |
| Phonophobia‐free | 43 (56) | 57 (70) | .06 |
| Nausea‐free | 49 (64) | 67 (82) | .01 |
a
Nominal P value ADAM zolmitriptan 3.8 mg vs placebo due fixed sequential testing.
b
Defined as improvement to a rating of none or mild without the use of rescue medications.